NanoString to develop a companion diagnostic for Merck's Keytruda
Expanding upon an agreement that began in May 2015, NanoString Technologies Inc. entered into a formal deal with Merck &Co. Inc. to develop a companion diagnostic for Merck's marketed cancer drug Keytruda (pembrolizumab).
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Nanotechnology, Chips, etc.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.